FDA Peptide Reclassification 2026: What It Means for Providers In the Pipeline: Top Drug Candidates for FDA Approval in 2024 The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Injectable and Topical Peptides in Aesthetic Medicine Mechanisms, Clinical Applications, and Future Potential PRIME Journal